Our latest
news

March 2025

Vascular inflammation and leukocytes trafficking in tumor progression

MesenFlow secures Innosuisse funding to develop next-generation vascularized organoid platforms for more predictive, human-relevant drug testing.

LEARN MORE

May 2022

Advancing inflammation research: MesenFlow validates Orion Biotechnology’s best-in-class CCR2 antagonist

Orion Biotechnology achieves full blockade of primary monocyte transmigration using MesenFlow’s human flow-based inflammation platform.

LEARN MORE

October 2021

MesenFlow Technologies contributes to the mechanism-of-action validation of N-Feruloyl Serotonin for skin-soothing innovation

MesenFlow validates the anti-inflammatory mechanism of N-Feruloyl Serotonin, supporting its launch as a next-generation skin-soothing cosmetic active.

LEARN MORE

December 2018

Circadian rhythms shape leukocyte trafficking and anti-tumor immunity

MesenFlow contributes to research revealing how circadian rhythms regulate leukocyte trafficking and shape anti-tumor immune responses.

LEARN MORE

January 2018

Vascular inflammation and leukocytes trafficking in tumor progression

MesenFlow highlights how vascular inflammation reshapes immune cell trafficking to drive tumor progression and influence anti-tumor immunity.

LEARN MORE

➔
contact us!

MesenFlow

MesenFlow Technologies SàrlAvenue de la Roseraie 64
1205, Geneva
Switzerland

contact@mesenflow.com

+41 22 32 16 961 (office)
+41 79 36 66 291 (mobile)

Contact us

➔
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
MESENFLOWTECHNOLOGYAPPROACHABOUTNEWS
SERVICESCELL ADHESION MODEL INFLAMMATION MODEL TUMOR-TARGETING MODELORGANOID MODEL
INFOCONTACTLINKEDINLEGAL NOTICEPRIVACY POLICY
MESENFLOW TECHNOLOGIESWEBSITE BY OBLIQUE